Medtronic plc (MDT) KPIs and segments
Close on Nov 18, 2026Market cap $128.83BP/E 24.7Yield 2.82%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Medtronic · năm tài chính kết thúc Last Friday of April (52/53-week fiscal year; FY2026 ended April 24, 2026; Q1 FY2027 14-week quarter ended July 31, 2026)
Nhìn nhanh KPI của Medtronic: 54 chỉ số vận hành, trong đó có Worldwide New Insulin Pumps Sold, Global CGM Sensor Attachment Rate và Diabetes Net Sales by Product Category, lấy từ 152 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Năm tài chính của Medtronic kết thúc Last Friday of April (52/53-week fiscal year; FY2026 ended April 24, 2026; Q1 FY2027 14-week quarter ended July 31, 2026) — Q1 FY27 = CQ2 2026 (quý dương lịch).
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Reportable segment net sales($M)2 | 8,884 | 6,662 | 8,985 | 8,926 | 7,785 | 6,141 | 8,260 | 8,366 | 7,967 | 6,044 | 8,035 | 7,923 | |
United States($M) | 4,649 | 3,914 | 4,475 | 4,494 | 3,988 | 3,608 | 4,223 | 4,286 | 4,064 | 3,465 | 4,100 | 4,151 | |
International($M) | 4,236 | 2,748 | 4,510 | 4,432 | 3,797 | 2,533 | 4,038 | 4,080 | 3,903 | 4,215 | 3,935 | 3,772 | |
Cardiovascular($M)4 | 3,927 | 3,797 | 3,457 | 3,436 | 3,285 | 3,336 | 3,037 | 3,102 | 3,007 | 3,129 | 2,929 | 2,923 | |
International($M) | 2,074 | 2,022 | 1,868 | 1,844 | 1,806 | 1,773 | 1,632 | 1,668 | 1,604 | 1,682 | 1,556 | 1,496 | |
United States($M) | 1,853 | 1,775 | 1,589 | 1,592 | 1,479 | 1,562 | 1,405 | 1,434 | 1,403 | 1,448 | 1,373 | 1,427 | |
Non-U.S. Developed Markets($M) | 1,039 | 950 | 912 | ||||||||||
Emerging Markets($M) | 643 | 607 | 584 | ||||||||||
Neuroscience($M)4 | 2,678 | 2,751 | 2,558 | 2,562 | 2,427 | 2,620 | 2,458 | 2,451 | 2,317 | 2,545 | 2,355 | 2,288 | |
United States($M) | 1,813 | 1,812 | 1,709 | 1,730 | 1,624 | 1,782 | 1,689 | 1,677 | 1,565 | 1,691 | 1,556 | 1,560 | |
International($M) | 864 | 938 | 849 | 832 | 803 | 838 | 769 | 774 | 752 | 853 | 799 | 728 | |
Non-U.S. Developed Markets($M) | 482 | 442 | 310 | ||||||||||
Emerging Markets($M) | 371 | 357 | 84 | ||||||||||
Medical Surgical($M)4 | 2,279 | 2,387 | 2,173 | 2,171 | 2,073 | 2,211 | 2,072 | 2,128 | 1,996 | 2,198 | 2,112 | 2,103 | |
International($M) | 1,297 | 1,366 | 1,244 | 1,228 | 1,188 | 1,266 | 1,180 | 1,183 | 1,115 | 1,244 | 1,164 | 1,155 | |
United States($M) | 982 | 1,022 | 929 | 943 | 884 | 946 | 893 | 944 | 881 | 954 | 947 | 948 | |
Non-U.S. Developed Markets($M) | 779 | 758 | 399 | ||||||||||
Emerging Markets($M) | 396 | 429 | 329 | ||||||||||
Other Operating Segments, Including Diabetes($M) | 872 | 755 | |||||||||||
Diabetes($M)4 | 843 | 838 | 796 | 757 | 721 | 728 | 694 | 686 | 647 | 659 | 640 | 610 | |
International($M) | 603 | 599 | 548 | 527 | 504 | 488 | 457 | 455 | 432 | 436 | 416 | 394 | |
United States($M) | 240 | 239 | 248 | 230 | 217 | 240 | 236 | 232 | 215 | 223 | 224 | 217 | |
Non-U.S. Developed Markets($M) | 337 | 322 | 740 | ||||||||||
Emerging Markets($M) | 99 | 94 | 438 | ||||||||||
Other Operating Segments($M)2 | 32 | 35 | 33 | 31 | 32 | 37 | 38 | 57 | 53 | 61 | |||
United States($M) | 17 | 21 | 18 | 22 | 20 | 17 | 15 | 18 | 18 | 26 | 20 | 23 | |
International($M) | 12 | 13 | 14 | 13 | 14 | 15 | 17 | 19 | 19 | 32 | 34 | 37 | |
Other operating segment, misc($M) | 29 | 33 | |||||||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2025)1 | |||||||||||||
United States($M) | 4,906 | 4,869 | 4,493 | 4,516 | 4,224 | 4,547 | 4,237 | 4,304 | 4,082 | 4,343 | 4,120 | 4,175 | |
International($M) | 4,850 | 4,938 | 4,524 | 4,445 | 4,354 | 4,379 | 4,055 | 4,099 | 3,832 | 4,247 | 3,968 | 3,809 | |
Rest of world($M) | 4,810 | 4,900 | 4,488 | 4,410 | 4,321 | 4,350 | 4,027 | 4,070 | 3,803 | 4,219 | 3,942 | 3,780 | |
Ireland($M) | 40 | 39 | 36 | 35 | 33 | 30 | 28 | 29 | 30 | 27 | 27 | 29 | |
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2 | |||||||||||||
Cardiovascular($M) | 1,033 | 1,068 | 899 | 877 | 828 | 955 | 828 | 781 | 780 | -220 | 1,090 | 1,117 | |
Neuroscience($M) | 793 | 879 | 737 | 740 | 713 | 858 | 762 | 725 | 687 | -31 | 994 | 929 | |
Medical Surgical($M) | 485 | 605 | 499 | 531 | 486 | 575 | 512 | 525 | 459 | -139 | 812 | 795 | |
Other Operating Segments, Including Diabetes($M) | 74 | 37 | |||||||||||
Diabetes($M) | 57 | 53 | 26 | 383 | 50 | 33 | 24 | 90 | 118 | 101 | |||
Other Operating Segments($M) | -1 | 9 | 11 | 13 | 12 | 13 | |||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2025)1 | |||||||||||||
Cardiovascular($M) | 2,619 | 2,528 | 2,298 | 2,302 | 2,153 | 2,213 | 2,073 | 2,052 | 2,009 | ||||
Neuroscience($M) | 1,892 | 1,908 | 1,743 | 1,790 | 1,703 | 1,832 | 1,746 | 1,712 | 1,660 | ||||
Medical Surgical($M) | 1,360 | 1,423 | 1,306 | 1,340 | 1,261 | 1,341 | 1,284 | 1,309 | 1,218 | ||||
Diabetes($M) | 464 | 441 | 417 | 455 | 410 | 398 | 375 | ||||||
Medical Surgical($M) | 31,905 | 32,535 | 32,748 | 32,984 | 33,326 | 33,317 | 33,586 | ||||||
Neuroscience($M) | 19,942 | 18,514 | 18,447 | 18,479 | 18,433 | 18,476 | 18,270 | ||||||
Cardiovascular($M) | 17,517 | 17,553 | 16,748 | 16,663 | 16,573 | 16,548 | 16,128 | ||||||
Other Operating Segments, Including Diabetes($M) | 4,827 | 4,433 | |||||||||||
Other Operating Segments($M) | 4,747 | 4,827 | 207 | 216 | 202 | 296 | 547 | ||||||
Diabetes($M) | 4,312 | 4,271 | 4,209 | 4,136 | 3,996 | ||||||||
Remaining performance obligations (RPO)($M) | 400 | 400 | 300 | 400 | 400 | 400 | 400 | 500 | 500 | ||||
Worldwide New Insulin Pumps Sold (thousands of units)(M) | 34.4 | 41.9 | 39 | 32.1 | 31.9 | 43 | 36.9 | 33.9 | 31.5 | ||||
Global CGM Sensor Attachment Rate (%)(%) | 69.0% | 68.0% | 67.0% | 65.0% | 64.0% | 63.0% | 61.0% | 59.0% | 57.0% | ||||
Diabetes Net Sales by Product Category ($M)($M)4 | 843 | 837 | 790 | 752 | 723 | 724 | 687 | 682 | 623 | ||||
CGM Sensors & Transmitters Revenue ($M)($M) | 431 | 420 | 390 | 383 | 360 | 345 | 330 | 334 | 304 | ||||
Infusion Sets & Reservoirs (Pump Consumables) Revenue ($M)($M) | 261 | 249 | 244 | 234 | 229 | 223 | 213 | 210 | 209 | ||||
Durable Insulin Pumps Hardware Revenue ($M)($M) | 144 | 146 | 151 | 131 | 119 | 154 | 136 | 128 | 123 | ||||
Smart Pens & Other Diabetes Products Revenue ($M)($M) | 7 | 22 | 5 | 4 | 15 | 2 | 8 | 9 | -13 | ||||
Diabetes Portfolio (Consolidated Segment) — Worldwide Revenue ($M)($M)7 | 843 | 837 | 796 | 757 | 721 | 728 | 694 | 686 | 647 | 660 | 640 | 610 | |
Medtronic Consolidated — Worldwide Revenue ($M)($M)8 | 9,756 | 9,807 | 9,017 | 8,961 | 8,578 | 8,927 | 8,292 | 8,403 | 7,915 | 8,589 | 8,089 | 7,984 | |
Consolidated Gross Margin Pricing Realization Benefit YoY (bps)(bps) | 30 | 30 | 30 | 30 | 30 | ||||||||
Medtronic Consolidated — Organic Revenue Growth YoY (%)(%) | 13.7% | 6.6% | 6.0% | 5.5% | 4.8% | 5.4% | 4.1% | 5.0% | 5.3% | 5.4% | 4.6% | 5.0% | |
Medtronic Consolidated — Foreign Currency Impact ($M)($M) | 57 | 308 | 243 | 111 | 162 | -96 | -104 | 45 | -93 | -75 | 68 | 85 | |
Medtronic Consolidated — Reported Revenue Growth YoY (%)(%) | 13.7% | 9.9% | 8.7% | 6.6% | 8.4% | 3.9% | 2.5% | 5.3% | 2.8% | 0.5% | 4.7% | 5.3% | |
Medtronic Consolidated — U.S. Revenue ($M)($M)1 | 4,906 | 4,869 | 4,493 | 4,516 | 4,224 | 4,547 | 4,237 | 4,304 | 4,082 | 4,343 | 4,120 | 4,175 | |
Medtronic Consolidated — International Revenue ($M)($M)2 | 4,850 | 4,938 | 4,524 | 4,445 | 4,354 | 4,380 | 4,055 | 4,099 | 3,832 | 4,246 | 3,968 | 3,809 | |
Medtronic Consolidated — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M)($M)1 | 2,674 | 2,473 | 2,368 | ||||||||||
Medtronic Consolidated — Emerging Markets Revenue (Legacy through FY2024Q4, $M)($M)1 | 1,572 | 1,495 | 1,441 | ||||||||||
Cardiovascular Portfolio — Worldwide Revenue ($M)($M)9 | 3,927 | 3,797 | 3,457 | 3,436 | 3,285 | 3,336 | 3,037 | 3,102 | 3,007 | 3,130 | 2,929 | 2,923 | |
Cardiac Ablation Solutions (CAS / PFA) — Global Organic Growth YoY (%)(%)2 | 88.0% | 78.0% | 80.0% | 71.0% | |||||||||
Cardiac Ablation Solutions (CAS) — U.S. Organic Growth YoY (%)(%) | 139.0% | 124.0% | 137.0% | ||||||||||
Cardiac Ablation Solutions (CAS) — U.S. Market Share Gain YoY (percentage points)(%) | 9.0% | 8.0% | 4.0% | ||||||||||
Cardiac Rhythm Management (CRM) — Global Organic Growth YoY (%)(%) | 15.0% | 5.0% | 5.0% | 5.0% | 3.0% | ||||||||
Cardiovascular Portfolio — Organic Revenue Growth YoY (%)(%) | 18.9% | 10.1% | 10.6% | 9.3% | 7.0% | 7.8% | 5.0% | 5.6% | 6.9% | 4.0% | 5.1% | 4.8% | |
Cardiovascular Portfolio — Foreign Currency Impact ($M)($M) | 21 | 124 | 99 | 46 | 68 | -37 | -38 | 16 | -39 | -28 | 28 | 31 | |
Cardiovascular Portfolio — Reported Revenue Growth YoY (%)(%) | 19.5% | 13.8% | 13.8% | 10.8% | 9.3% | 6.6% | 3.7% | 6.1% | 5.5% | -5.2% | 6.1% | 5.9% | |
Cardiovascular Portfolio — U.S. Revenue ($M)($M)1 | 1,853 | 1,775 | 1,589 | 1,592 | 1,479 | 1,563 | 1,405 | 1,434 | 1,403 | 1,448 | 1,373 | 1,427 | |
Cardiovascular Portfolio — International Revenue ($M)($M)2 | 2,074 | 2,023 | 1,868 | 1,844 | 1,806 | 1,773 | 1,632 | 1,668 | 1,604 | 1,682 | 1,556 | 1,496 | |
Cardiovascular Portfolio — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M)($M)1 | 1,039 | 950 | 912 | ||||||||||
Cardiovascular Portfolio — Emerging Markets Revenue (Legacy through FY2024Q4, $M)($M)1 | 643 | 607 | 584 | ||||||||||
Cardiac Rhythm & Heart Failure (CRHF — Legacy through FY2026Q4) — Worldwide Revenue ($M)($M)5 | 2,110 | 1,856 | 1,825 | 1,712 | 1,733 | 1,545 | 1,578 | 1,535 | 1,587 | 1,470 | 1,492 | ||
Structural Heart & Aortic (SHA — Legacy through FY2026Q4) — Worldwide Revenue ($M)($M)5 | 1,002 | 929 | 956 | 930 | 944 | 874 | 881 | 856 | 883 | 843 | 819 | ||
Coronary & Peripheral Vascular (CPV — Legacy through FY2026Q4) — Worldwide Revenue ($M)($M)5 | 685 | 672 | 655 | 643 | 659 | 618 | 643 | 616 | 660 | 616 | 613 | ||
Neuroscience Portfolio — Worldwide Revenue ($M)($M)7 | 2,678 | 2,751 | 2,558 | 2,562 | 2,427 | 2,620 | 2,458 | 2,451 | 2,317 | 2,545 | 2,355 | 2,288 | |
Neuroscience Portfolio — Organic Revenue Growth YoY (%)(%) | 9.3% | 3.0% | 2.5% | 3.9% | 3.1% | 3.7% | 5.2% | 6.7% | 5.3% | 6.5% | 4.3% | 4.2% | |
Neuroscience Portfolio — Foreign Currency Impact ($M)($M) | 6 | 52 | 38 | 15 | 27 | -18 | -21 | 10 | -18 | -21 | 10 | 10 | |
Neuroscience Portfolio — Reported Revenue Growth YoY (%)(%) | 10.3% | 5.0% | 4.1% | 4.5% | 4.3% | 2.9% | 4.4% | 7.1% | 4.4% | 5.6% | 4.8% | 4.7% | |
Neuroscience Portfolio — U.S. Revenue ($M)($M)1 | 1,813 | 1,812 | 1,709 | 1,730 | 1,624 | 1,782 | 1,689 | 1,677 | 1,565 | 1,692 | 1,556 | 1,560 | |
Neuroscience Portfolio — International Revenue ($M)($M)2 | 864 | 938 | 849 | 832 | 803 | 838 | 769 | 774 | 752 | 853 | 799 | 728 | |
Neuroscience Portfolio — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M)($M)1 | 482 | 442 | 399 | ||||||||||
Neuroscience Portfolio — Emerging Markets Revenue (Legacy through FY2024Q4, $M)($M)1 | 371 | 357 | 329 | ||||||||||
Cranial & Spinal Technologies (CST) — Worldwide Revenue ($M)($M)6 | 1,365 | 1,403 | 1,310 | 1,299 | 1,211 | 1,342 | 1,250 | 1,234 | 1,147 | 1,291 | 1,204 | 1,157 | |
Core Spine Hardware — Global Organic Revenue Growth YoY (%)(%) | 14.0% | 6.0% | 8.0% | 8.0% | |||||||||
Cranial & Spinal Technologies (CST) — Organic Revenue Growth YoY (%)(%) | 12.9% | 3.3% | 3.7% | 4.7% | 4.5% | 4.4% | 4.6% | 6.4% | 4.8% | 8.7% | 6.5% | 6.7% | |
Cranial & Spinal Technologies (CST) — Foreign Currency Impact ($M)($M) | -2 | 18 | 13 | 6 | 12 | -7 | -9 | 3 | -9 | -11 | 3 | 4 | |
Cranial & Spinal Technologies (CST) — Reported Revenue Growth YoY (%)(%) | 12.8% | 4.6% | 4.8% | 5.2% | 5.5% | 3.9% | 3.8% | 6.7% | 4.0% | 7.8% | 6.7% | 7.0% | |
Cranial & Spinal Technologies (CST) — U.S. Revenue ($M)($M)1 | 1,016 | 1,031 | 977 | 966 | 890 | 999 | 943 | 926 | 855 | 936 | 875 | 863 | |
Cranial & Spinal Technologies (CST) — International Revenue ($M)($M)2 | 349 | 372 | 333 | 332 | 320 | 343 | 307 | 308 | 292 | 356 | 329 | 293 | |
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Worldwide Revenue ($M)($M)5 | 774 | 806 | 746 | 744 | 702 | 759 | 732 | 737 | 713 | 778 | 726 | 705 | |
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Organic Revenue Growth YoY (%)(%) | 7.4% | 3.4% | -0.2% | 0.3% | -2.7% | -1.6% | 1.9% | 3.9% | 3.4% | 3.1% | 3.4% | 2.6% | |
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Foreign Currency Impact ($M)($M) | 6 | 21 | 15 | 5 | 9 | -7 | -8 | 5 | -7 | -9 | 3 | 1 | |
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Reported Revenue Growth YoY (%)(%) | 10.2% | 6.2% | 1.9% | 0.9% | -1.5% | -2.5% | 0.8% | 4.6% | 2.5% | 2.0% | 3.9% | 2.8% | |
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — U.S. Revenue ($M)($M) | 447 | 431 | 402 | 409 | 393 | 431 | 419 | 418 | 398 | 439 | 407 | 403 | |
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — International Revenue ($M)($M)2 | 326 | 374 | 343 | 335 | 309 | 328 | 313 | 319 | 314 | 339 | 319 | 302 | |
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — Worldwide Revenue ($M)($M)5 | 539 | 542 | 503 | 520 | 514 | 520 | 476 | 480 | 457 | 475 | 425 | 426 | |
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — Organic Revenue Growth YoY (%)(%) | 3.3% | 1.7% | 3.6% | 7.3% | 8.6% | 10.2% | 12.9% | 12.1% | 9.6% | 6.0% | 0.2% | 0.5% | |
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — Foreign Currency Impact ($M)($M) | 2 | 13 | 10 | 5 | 7 | -4 | -4 | 2 | -3 | -1 | 4 | 5 | |
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — Reported Revenue Growth YoY (%)(%) | 4.7% | 4.3% | 5.8% | 8.3% | 10.2% | 9.3% | 12.0% | 12.6% | 8.9% | 5.8% | 1.2% | 1.7% | |
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — U.S. Revenue ($M)($M)1 | 350 | 350 | 330 | 355 | 341 | 352 | 327 | 333 | 312 | 317 | 275 | 293 | |
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — International Revenue ($M)($M)2 | 189 | 191 | 173 | 165 | 174 | 167 | 149 | 146 | 146 | 158 | 150 | 133 | |
Medical Surgical Portfolio — Worldwide Revenue ($M)($M)7 | 2,279 | 2,388 | 2,173 | 2,171 | 2,073 | 2,212 | 2,072 | 2,128 | 1,996 | 2,198 | 2,112 | 2,103 | |
Medical Surgical Portfolio — Organic Revenue Growth YoY (%)(%) | 10.2% | 5.1% | 2.7% | 1.3% | 2.4% | 2.0% | -0.4% | 0.7% | 1.0% | 4.5% | 2.9% | 5.6% | |
Medical Surgical Portfolio — Foreign Currency Impact ($M)($M) | 15 | 81 | 61 | 27 | 40 | -30 | -32 | 10 | -29 | -22 | 20 | 27 | |
Medical Surgical Portfolio — Reported Revenue Growth YoY (%)(%) | 10.0% | 8.0% | 4.9% | 2.1% | 4.4% | 0.6% | -1.9% | 1.2% | -0.4% | 3.5% | 3.9% | 7.0% | |
Medical Surgical Portfolio — U.S. Revenue ($M)($M)1 | 982 | 1,021 | 929 | 943 | 884 | 946 | 893 | 944 | 881 | 954 | 947 | 948 | |
Medical Surgical Portfolio — International Revenue ($M)($M)2 | 1,297 | 1,366 | 1,244 | 1,228 | 1,188 | 1,266 | 1,180 | 1,183 | 1,115 | 1,244 | 1,164 | 1,155 | |
Medical Surgical Portfolio — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M)($M)1 | 805 | 758 | 740 | ||||||||||
Medical Surgical Portfolio — Emerging Markets Revenue (Legacy through FY2024Q4, $M)($M)1 | 439 | 429 | 438 | ||||||||||
Surgical & Endoscopy — Worldwide Revenue ($M)($M)5 | 1,740 | 1,820 | 1,654 | 1,679 | 1,601 | 1,709 | 1,596 | 1,649 | 1,544 | 1,705 | 1,616 | 1,641 | |
Surgical & Endoscopy — Organic Revenue Growth YoY (%)(%) | 9.0% | 3.5% | 1.4% | 1.1% | 2.3% | 1.7% | 0.4% | 1.3% | 5.0% | 3.4% | 6.8% | ||
Surgical & Endoscopy — Foreign Currency Impact ($M)($M) | 14 | 69 | 51 | 23 | 32 | -25 | -26 | 9 | -22 | -15 | 18 | 25 | |
Surgical & Endoscopy — Reported Revenue Growth YoY (%)(%) | 8.7% | 6.5% | 3.6% | 1.8% | 4.4% | 0.2% | -1.2% | 0.5% | -0.1% | 4.1% | 4.5% | 8.5% | |
Surgical & Endoscopy — U.S. Revenue ($M)($M)1 | 671 | 694 | 634 | 665 | 622 | 668 | 623 | 675 | 630 | 679 | 663 | 688 | |
Surgical & Endoscopy — International Revenue ($M)($M)2 | 1,070 | 1,126 | 1,020 | 1,014 | 980 | 1,041 | 973 | 974 | 915 | 1,026 | 953 | 953 | |
Acute Care & Monitoring — Worldwide Revenue ($M)($M)5 | 539 | 568 | 519 | 493 | 471 | 503 | 476 | 478 | 452 | 492 | 495 | 462 | |
Acute Care & Monitoring — Organic Revenue Growth YoY (%)(%) | 14.2% | 10.5% | 7.0% | 2.0% | 2.6% | 3.1% | -2.8% | 3.3% | -0.1% | 2.5% | |||
Acute Care & Monitoring — Foreign Currency Impact ($M)($M) | 1 | 12 | 10 | 4 | 8 | -5 | -5 | 1 | -6 | -6 | |||
Acute Care & Monitoring — Reported Revenue Growth YoY (%)(%) | 14.4% | 12.9% | 9.1% | 3.0% | 4.3% | 2.1% | -3.9% | 3.6% | -1.5% | 1.2% | |||
Acute Care & Monitoring — U.S. Revenue ($M)($M)1 | 311 | 328 | 295 | 278 | 263 | 278 | 269 | 269 | 251 | 275 | 284 | 260 | |
Acute Care & Monitoring — International Revenue ($M)($M)2 | 228 | 240 | 224 | 214 | 209 | 225 | 206 | 209 | 200 | 217 | 211 | 202 | |
Cardiovascular — Segment R&D Expense ($M)($M)4 | 303 | 273 | 284 | 299 | 280 | 259 | 248 | 256 | 257 | ||||
Cardiovascular — Segment SG&A Expense ($M)($M) | 1,269 | 1,188 | 1,129 | 1,143 | 1,060 | 1,012 | 1,010 | 1,021 | 978 | ||||
Cardiovascular — Segment Depreciation Expense ($M)($M) | 71 | 67 | 66 | 56 | 64 | 58 | 56 | 56 | 55 | ||||
Cardiovascular — Segment Other Operating Expense ($M)($M) | 14 | -1 | -14 | -17 | -15 | -14 | -14 | -7 | -6 | ||||
Cardiovascular — Segment Goodwill Balance ($M)($M) | 8,583 | 8,602 | 8,037 | 8,028 | 8,045 | 8,017 | 7,929 | 7,970 | 7,977 | 7,966 | 7,906 | 7,849 | |
Neuroscience — Segment R&D Expense ($M)($M)4 | 163 | 139 | 153 | 167 | 157 | 149 | 152 | 158 | 153 | ||||
Neuroscience — Segment SG&A Expense ($M)($M) | 922 | 875 | 841 | 874 | 831 | 813 | 820 | 834 | 808 | ||||
Neuroscience — Segment Depreciation Expense ($M)($M) | 78 | 85 | 80 | 79 | 77 | 72 | 73 | 71 | 65 | ||||
Neuroscience — Segment Other Operating Expense ($M)($M) | 13 | 13 | 12 | 9 | 2 | 12 | 12 | -4 | 11 | ||||
Neuroscience — Segment Goodwill Balance ($M)($M) | 12,673 | 11,777 | 11,757 | 11,738 | 11,754 | 11,716 | 11,611 | 11,668 | 11,654 | 11,644 | 11,674 | 11,634 | |
Medical Surgical — Segment R&D Expense ($M)($M)4 | 189 | 163 | 174 | 181 | 169 | 169 | 164 | 171 | 162 | ||||
Medical Surgical — Segment SG&A Expense ($M)($M) | 681 | 650 | 628 | 627 | 605 | 593 | 605 | 609 | 591 | ||||
Medical Surgical — Segment Depreciation Expense ($M)($M) | 65 | 56 | 62 | 53 | 54 | 53 | 51 | 51 | 49 | ||||
Medical Surgical — Segment Other Operating Expense ($M)($M) | 5 | 5 | 6 | 2 | 1 | 4 | 4 | 5 | 5 | ||||
Medical Surgical — Segment Goodwill Balance ($M)($M) | 19,675 | 19,953 | 19,842 | 19,788 | 19,952 | 19,748 | 19,025 | 19,268 | 19,198 | 19,121 | 19,325 | 19,084 | |
Corporate & Shared Functions — Depreciation Expense ($M)($M) | 69 | 68 | 68 | 61 | 64 | 62 | 57 | 57 | 53 | ||||
Remaining Performance Obligations / Contracted Backlog ($M)($M)3 | 400 | 400 | 400 | 300 | 400 | 300 | 400 | 400 | 400 | 500 | 500 | 500 | |
Deferred Revenue / Customer Contract Liabilities ($M)($M)1 | 500 | 500 | 468 | 451 | 442 | 446 | 462 | 467 | 461 | 453 | 447 | 435 | |
Revenue Recognized from Opening Contract Liability Balance ($M)($M) | 140 | 85 | 85 | 94 | 135 | 69 | 55 | 88 | 108 | 50 | 58 | 92 | |
Collaborative Arrangement Revenue ($M)($M) | 12 | 34 | 36 | 37 | 36 | 48 | 50 | 46 | 38 | ||||
Allowance for Credit Losses on Accounts Receivable ($M)($M) | 203 | 190 | 207 | 200 | 204 | 199 | 204 | 195 | 170 | 173 | 180 | 177 | |
Inventories by Production Stage — Total ($M)($M)3 | 6,215 | 5,951 | 6,309 | 6,156 | 5,886 | 5,476 | 5,610 | 5,479 | 5,414 | 5,217 | 5,726 | 5,754 | |
Finished Goods Inventory ($M)($M) | 4,121 | 4,075 | 4,194 | 4,195 | 4,022 | 3,779 | 3,740 | 3,729 | 3,732 | 3,668 | 3,799 | 3,775 | |
Work in Process (WIP) Inventory ($M)($M) | 900 | 800 | 883 | 853 | 792 | 744 | 782 | 728 | 696 | 642 | 788 | 833 | |
Raw Materials & Supplies Inventory ($M)($M) | 1,194 | 1,076 | 1,232 | 1,108 | 1,072 | 953 | 1,089 | 1,022 | 986 | 907 | 1,139 | 1,147 | |
Intangible Asset Amortization Expense ($M)($M)9 | 412 | 436 | 441 | 463 | 459 | 557 | 416 | 413 | 414 | 400 | 419 | 425 | |
Quarterly Share Repurchases — Total Shares Purchased (millions)(M)3 | 2.77 | 4.51 | 0.92 | 3.30 | 1.39 | 2.91 | 1.93 | 2.88 | 30.3 | 19.5 | 1.60 | 2.34 | |
Stock-Based Compensation Expense by Award Type ($M)($M)5 | 125 | 95 | 95 | 182 | 86 | 89 | 98 | 159 | 83 | 90 | 85 | 146 | |
Unrecognized Tax Benefits (UTB) Balance ($M)($M)2 | 2,900 | 3,000 | 2,900 | 2,900 | 2,900 | 2,902 | 2,900 | 2,900 | 2,800 | 2,824 | 2,800 | 2,800 | |
Non-GAAP Operating Profit ($M)($M)10 | 2,316 | 2,500 | 2,177 | 2,162 | 2,016 | 2,486 | 2,169 | 2,041 | 1,953 | 2,311 | 2,042 | 2,009 | |
MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M)($M)19 | 843 | 837 | 790 | 752 | 723 | 724 | 687 | 682 | 623 | ||||
MiniMed — Organic Revenue Growth YoY (%)(%) | 15.8% | 8.7% | 8.6% | 7.8% | |||||||||
MiniMed — U.S. Net Sales ($M)($M) | 240 | 238 | 242 | 224 | 212 | 234 | 231 | 227 | 211 | ||||
MiniMed — International Net Sales ($M)($M) | 603 | 599 | 548 | 527 | 511 | 489 | 456 | 455 | 412 | ||||
MiniMed — Adjusted Standalone EBITDA ($M)($M) | 83 | 154 | 127 | 117 | 85 | 118 | 107 | 87 | 68 | ||||
MiniMed — Adjusted EBITDA ($M)($M) | 83 | -16 | 89 | 78 | 50 | 83 | 73 | ||||||
MiniMed — Adjusted Gross Profit ($M)($M) | 471 | 487 | 457 | 434 | 409 | 411 | 401 | ||||||
MiniMed — Adjusted Standalone Operating Income ($M)($M) | -68 | -53 | 74 | 48 | 60 | 66 | 47 | 9 | |||||
MiniMed — Adjusted Standalone Net Income ($M)($M) | -53 | -44 | 59 | 38 | 48 | 53 | 37 | 7 | |||||
MiniMed — GAAP Gross Profit ($M)($M) | 465 | 480 | 362 | 428 | 409 | 405 | 395 | 386 | 342 | ||||
MiniMed — GAAP R&D Expense ($M)($M) | 115 | 99 | 114 | 111 | 125 | 107 | 112 | 112 | 105 | ||||
MiniMed — GAAP SG&A Expense ($M)($M) | 312 | 299 | 309 | 293 | 283 | 276 | 268 | 271 | 265 | ||||
MiniMed — GAAP Operating Income / (Loss) ($M)($M) | 5 | -91 | -100 | 16 | -13 | -148 | 21 | 7 | -27 | ||||
MiniMed — GAAP Net Income / (Loss) ($M)($M) | 0 | -183 | -111 | -5 | -16 | -168 | -7 | -5 | -19 | ||||
MiniMed — Standalone Inventories ($M)($M)3 | 356 | 341 | 408 | 311 | |||||||||
MiniMed — Finished Goods Inventory ($M)($M) | 193 | 179 | 199 | 185 | |||||||||
MiniMed — Work in Process Inventory ($M)($M) | 35 | 34 | 44 | 38 | |||||||||
MiniMed — Raw Materials Inventory ($M)($M) | 128 | 128 | 164 | 87 | |||||||||
MiniMed — Standalone Remaining Performance Obligations ($M)($M) | 46 | 39 | 23 | ||||||||||
MiniMed — Standalone Contract Liabilities ($M)($M) | 19 | 19 | 17 | 15 | |||||||||
MiniMed — Customer Refund & Return Liabilities ($M)($M) | 42 | 45 | 48 | 51 | |||||||||
MiniMed — Property, Plant & Equipment, Net ($M)($M) | 736 | 711 | 701 | 706 | |||||||||
MiniMed — Goodwill ($M)($M) | 2,300 | 2,300 | 2,300 | 2,300 | |||||||||
FDA 510(k) Premarket Clearances — Medtronic1 | 9 | 12 | 12 | 8 | 9 | 3 | 7 | 6 | 7 | 7 | 3 | 8 | |
FDA 510(k) Premarket Clearances — U.S. Industry Total | 889 | 835 | 736 | 823 | 882 | 767 | 812 | 814 | 793 | 750 | 780 | 941 | |
FDA Premarket Approvals (PMA & Supplements) — Medtronic1 | 114 | 168 | 93 | 135 | 147 | 129 | 159 | 95 | 120 | 132 | 147 | 139 | |
FDA Premarket Approvals (PMA & Supplements) — U.S. Industry Total | 616 | 641 | 434 | 613 | 597 | 564 | 607 | 569 | 575 | 486 | 582 | 600 | |
FDA Medical Device Recall Events — Medtronic1 | 28 | 18 | 10 | 6 | 6 | 18 | 12 | 11 | 42 | 9 | 16 | 14 | |
FDA Device Enforcement Reports — Medtronic | 23 | 17 | 10 | 6 | 7 | 18 | 11 | 11 | 43 | 8 | 23 | 8 | |
FDA MAUDE Adverse Event Reports — Medtronic Total4 | 97,049 | 104,151 | 84,369 | 101,865 | 81,659 | 66,228 | 74,539 | 67,798 | 69,110 | 64,204 | 70,949 | 73,691 | |
ClinicalTrials.gov Newly Started Studies — Medtronic | 12 | 14 | 11 | 15 | 9 | 17 | 10 | 8 | 5 | 9 | 12 | 10 | |
Cardiovascular — Segment Revenue ($M, DB)($M)1 | 3,927 | 3,797 | 3,457 | 3,436 | 3,285 | 3,336 | 3,037 | 3,102 | 3,007 | 3,129 | 2,929 | 2,923 | |
Neuroscience — Segment Revenue ($M, DB)($M)1 | 2,678 | 2,751 | 2,558 | 2,562 | 2,427 | 2,620 | 2,458 | 2,451 | 2,317 | 2,545 | 2,355 | 2,288 | |
Medical Surgical — Segment Revenue ($M, DB)($M)1 | 2,279 | 2,387 | 2,173 | 2,171 | 2,073 | 2,211 | 2,072 | 2,128 | 1,996 | 2,198 | 2,112 | 2,103 | |
Consolidated Net Sales / Revenue ($M, DB)($M)9 | 9,756 | 9,807 | 9,017 | 8,961 | 8,578 | 8,927 | 8,292 | 8,403 | 7,915 | 8,589 | 8,089 | 7,984 | |
Total Assets ($M, DB)($M)8 | 93,306 | 93,028 | 91,485 | 91,346 | 90,972 | 91,680 | 89,973 | 90,042 | 89,749 | 89,981 | 90,836 | 90,087 | |
Operating Cash Flow ($M, DB)($M)3 | 1,793 | 2,573 | 2,744 | 925 | 1,088 | 2,528 | 2,572 | 958 | 986 | 2,777 | 2,474 | 661 | |
41 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Core Operational & Franchise KPIs (Groups 1–2): Diabetes hardware unit volume (Worldwide New Pumps Sold in thousands), Global CGM Attachment Rate (%), recurring sensor/consumable vs. pump hardware revenue mix, Consolidated Gross Margin Pricing Benefit (bps), flagship franchise organic growth (Cardiac Ablation Solutions / PFA, Cardiac Rhythm Management, Core Spine), and all active + legacy Operating Divisions across Worldwide, U.S., and International markets.
- Cardiovascular Q1 FY2027 Reorganization & Legacy Geography (Step 5): In Q1 FY2027 (14-week quarter ended July 31, 2026), Medtronic reorganized Cardiovascular from 3 divisions (CRHF, SHA, CPV) into 4 divisions (EP Therapies, IC Therapies, CV Surgery, PV Health) without Q2–Q4 FY2026 restated quarters yet; the 3 legacy divisions are retained through FY2026Q4 while the 4 new divisions (<3 consecutive quarters) are listed in excluded. Similarly, Non-U.S. Developed & Emerging Markets revenue/organic growth are retained as legacy rows through FY2024Q4 alongside International division tables (FY2024Q1–FY2027Q1).
- Consolidated − Standalone Assessment (Step 3 & Step 4): Medtronic plc files consolidated financial statements in Form 10-K/10-Q without SEC Schedule I parent-only financial statements; in its Irish Statutory Reports, parent Medtronic plc is a pure holding company (zero operating turnover). Therefore consolidated − parent subtraction is not applicable. Instead, listed subsidiary MiniMed Group, Inc. (Nasdaq: MMED, CIK 0002062583 — IPO March 2026, split-off completed Oct 19, 2026) and Medtronic Limited (UK Co. 01070807) are tracked directly from their self-reported filings in Group 6.
- Period Splitting (Step 4): Only YTD subtraction (YTD − prior YTD and FY − 9M / Q4 = full year − nine months) is used where 10-K/10-Q/8-K report cumulative year-to-date cash flows or segment/XBRL totals. Zero self-computed ratios, margins, YoY rates, or sums exist anywhere in output/kpis.json.
Không hiện vì thiếu các kỳ gần đây (88)
- MiniMed Worldwide Installed Pump Users (~659,000 users) — Disclosed only for a single period (FY2026) as '~659K' / 'more than 650,000' (bound / <3 periods); excluded per Step 5.
- Annual Patients Served Worldwide ('78M+', '79M+', '82M+') — Disclosed only with '+' lower-bound qualifier in Earnings Presentations and Letters; excluded per Step 5 bound rule.
- Cardiac Ablation Solutions FY2026Q1 Global Growth ('nearly 50%') & U.S. Growth ('over 70%') — Qualified as bounds in Q1 FY26; series starts at FY2026Q2 where exact point figures (71%, 80%, 78%, 88%) are published.
- Organizational Health Survey Employee Response Rate ('more than 88%' in FY2025 vs. 87% in FY2026) — FY2025 disclosed only as bound ('more than 88%'), leaving <2 consecutive point years.
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Organic Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Foreign Currency Impact ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Reported Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — U.S. Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — U.S. Organic Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — U.S. Revenue ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Organic Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Foreign Currency Impact ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Revenue ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Organic Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Foreign Currency Impact ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Reported Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — U.S. Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — U.S. Organic Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — U.S. Revenue ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Organic Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Foreign Currency Impact ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Revenue ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Organic Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Foreign Currency Impact ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Reported Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — U.S. Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — U.S. Organic Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — U.S. Revenue ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Organic Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Foreign Currency Impact ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Revenue ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Organic Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Foreign Currency Impact ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Reported Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — U.S. Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — U.S. Organic Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — U.S. Revenue ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Organic Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Foreign Currency Impact ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Revenue ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Worldwide Revenue ($M) › Specialty Therapies (Neurovascular, ENT & Pelvic Health) — U.S. Revenue ($M) › Specialty Therapies (Neurovascular, ENT & Pelvic Health) — U.S. Organic Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Surgical Innovations (Legacy through FY2023Q4) — Worldwide Revenue ($M) › Surgical Innovations (Legacy through FY2023Q4) — U.S. Revenue ($M) › Surgical Innovations (Legacy through FY2023Q4) — U.S. Organic Revenue Growth YoY (%)
- Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — Worldwide Revenue ($M) › Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — U.S. Revenue ($M) › Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — U.S. Organic Revenue Growth YoY (%)
- Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M) › Diabetes — Segment SG&A Expense ($M)
- Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M) › Diabetes — Segment Depreciation Expense ($M)
- Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M) › Diabetes — Segment Other Operating Expense ($M)
- Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M) › Diabetes — Segment Goodwill Balance ($M)
- Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Statutory Provisions for Liabilities — Total ($M) › Customer Rebates Provision Balance ($M) › U.S. GAAP Rebate Liability Offset Against Accounts Receivable ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Statutory Provisions for Liabilities — Total ($M) › Customer Rebates Provision Balance ($M) › U.S. GAAP Rebate Liability in Other Accrued Expenses ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Statutory Provisions for Liabilities — Total ($M) › MCS Product Exit Provision (FY2022–FY2023, $M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Manufacturing & R&D Equipment ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Computer Software & Enterprise Systems ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Buildings & Leasehold Improvements ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Construction in Progress — Capacity Expansion ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Land & Land Improvements ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › Operating Lease Cash Payments ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › ROU Assets Obtained in Exchange for New Operating Leases ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › Operating Lease Weighted-Average Discount Rate (%)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › Undiscounted Lease Commitments — Year +1 ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › Undiscounted Lease Commitments — Thereafter (>5 Years, $M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › Deferred Tax Assets Valuation Allowance ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › U.S. Defined Benefit Pension Projected Benefit Obligation ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › U.S. Defined Benefit Pension Fair Value of Plan Assets ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › Non-U.S. Defined Benefit Pension Projected Benefit Obligation ($M)
- Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › Non-U.S. Defined Benefit Pension Fair Value of Plan Assets ($M)
- Global Workforce, Manufacturing Space, Compensation & Sustainability (DEF 14A / Irish Statutory / 10-K / Form SD) › Scope 1 & 2 GHG Emissions Intensity Reduction vs. FY2020 Baseline (%) › Product Innovation Vitality Index — Revenue from Products Released in Prior 36M (%)
- Global Workforce, Manufacturing Space, Compensation & Sustainability (DEF 14A / Irish Statutory / 10-K / Form SD) › Scope 1 & 2 GHG Emissions Intensity Reduction vs. FY2020 Baseline (%) › Aggregate Product Complaint Rate Reduction vs. FY2020 Baseline (%)
- Subsidiaries Self-Reported Filings (MiniMed Group, Inc. & Medtronic Limited UK) › MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) › MiniMed — U.S. Net Sales ($M) › MiniMed — U.S. Organic Growth (%)
- Subsidiaries Self-Reported Filings (MiniMed Group, Inc. & Medtronic Limited UK) › MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) › MiniMed — International Net Sales ($M) › MiniMed — International Organic Growth (%)
- Subsidiaries Self-Reported Filings (MiniMed Group, Inc. & Medtronic Limited UK) › MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) › MiniMed — Operating Cash Flow ($M)
- Subsidiaries Self-Reported Filings (MiniMed Group, Inc. & Medtronic Limited UK) › MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) › MiniMed — Capital Expenditures ($M)
- External MedTech Regulatory, Clinical, Federal Procurement & Sector Benchmarks › U.S. PPI: Surgical & Medical Instrument Manufacturing (Index) › U.S. Hospitals Quarterly Revenue — Census QSS ($M)
- Reportable Segments & Geographic Context (Database) › Diabetes — Segment Revenue ($M, DB) › Diabetes — Segment Cost of Revenue ($M, DB)
- Reportable Segments & Geographic Context (Database) › Diabetes — Segment Revenue ($M, DB) › Diabetes — Segment Operating Income ($M, DB)
- Reportable Segments & Geographic Context (Database) › Diabetes — Segment Revenue ($M, DB) › Diabetes — Segment Total Assets ($M, DB)
- Reportable Segments & Geographic Context (Database) › Other Operating Segments — Revenue ($M, DB) › Other Operating Segments — Operating Income ($M, DB)
- Reportable Segments & Geographic Context (Database) › Other Operating Segments — Revenue ($M, DB)
- Reportable Segments & Geographic Context (Database) › United States — Geographic Revenue ($M, DB) › United States — Long-Lived Assets ($M, DB)
- Reportable Segments & Geographic Context (Database) › United States — Geographic Revenue ($M, DB) › Ireland — Long-Lived Assets ($M, DB)
- Reportable Segments & Geographic Context (Database) › United States — Geographic Revenue ($M, DB) › Other Countries ex-U.S. & Ireland — Long-Lived Assets ($M, DB)
- Consolidated Financial Statements Context (Database) › Consolidated Net Sales / Revenue ($M, DB) › Gross Profit ($M, DB)
- Consolidated Financial Statements Context (Database) › Consolidated Net Sales / Revenue ($M, DB) › GAAP Diluted EPS ($, DB)
- Consolidated Financial Statements Context (Database) › Consolidated Net Sales / Revenue ($M, DB) › Weighted-Average Diluted Shares (millions, DB)
- Consolidated Financial Statements Context (Database) › Consolidated Net Sales / Revenue ($M, DB) › Cash Dividends Declared per Ordinary Share ($, DB)
- Consolidated Financial Statements Context (Database) › Operating Cash Flow ($M, DB) › Acquisitions, Net of Cash Acquired ($M, DB)
Dữ liệu cập nhật 2026-10-31.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Diabetes Hardware & Recurring Consumable Drivers (Core KPIs)
Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary)
- Medtronic Consolidated — Worldwide Revenue ($M) ($M)47 kỳ
- Cardiovascular Portfolio — Worldwide Revenue ($M) ($M)26 kỳ
- Cardiac Rhythm & Heart Failure (CRHF — Legacy through FY2026Q4) — Worldwide Revenue ($M) ($M)46 kỳ
- Structural Heart & Aortic (SHA — Legacy through FY2026Q4) — Worldwide Revenue ($M) ($M)25 kỳ
- Coronary & Peripheral Vascular (CPV — Legacy through FY2026Q4) — Worldwide Revenue ($M) ($M)25 kỳ
- Neuroscience Portfolio — Worldwide Revenue ($M) ($M)26 kỳ
- Cranial & Spinal Technologies (CST) — Worldwide Revenue ($M) ($M)29 kỳ
- Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Worldwide Revenue ($M) ($M)45 kỳ
- Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — Worldwide Revenue ($M) ($M)33 kỳ
- Medical Surgical Portfolio — Worldwide Revenue ($M) ($M)26 kỳ
- Surgical & Endoscopy — Worldwide Revenue ($M) ($M)17 kỳ
- Acute Care & Monitoring — Worldwide Revenue ($M) ($M)14 kỳ
- Surgical Innovations (Legacy through FY2023Q4) — Worldwide Revenue ($M) ($M)24 kỳ
- Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — Worldwide Revenue ($M) ($M)24 kỳ
Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL)
Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges
- Remaining Performance Obligations / Contracted Backlog ($M) ($M)33 kỳ
- Statutory Provisions for Liabilities — Total ($M) ($M)6 kỳ
- Inventories by Production Stage — Total ($M) ($M)47 kỳ
- Intangible Asset Amortization Expense ($M) ($M)49 kỳ
- Quarterly Share Repurchases — Total Shares Purchased (millions) (M)35 kỳ
- Stock-Based Compensation Expense by Award Type ($M) ($M)49 kỳ
- Unrecognized Tax Benefits (UTB) Balance ($M) ($M)48 kỳ
- Non-GAAP Operating Profit ($M) ($M)45 kỳ
Global Workforce, Manufacturing Space, Compensation & Sustainability (DEF 14A / Irish Statutory / 10-K / Form SD)
- Global Employees — Exact Year-End Headcount (DEF 14A)7 kỳ
- Average Monthly Full-Time Equivalent (FTE) Employees — Total (Irish Statutory)6 kỳ
- Consolidated Employee Benefit Costs — Total ($M) ($M)6 kỳ
- CEO-to-Median Employee Pay Ratio (x) (×)8 kỳ
- Global Manufacturing & R&D Footprint (million sq ft) (triệu ft²)10 kỳ
- Scope 1 & 2 GHG Emissions Intensity Reduction vs. FY2020 Baseline (%) (%)5 kỳ
- 3TG Supply Chain — Potential Smelters or Refiners (SORs) Identified12 kỳ
Subsidiaries Self-Reported Filings (MiniMed Group, Inc. & Medtronic Limited UK)
External MedTech Regulatory, Clinical, Federal Procurement & Sector Benchmarks
- FDA 510(k) Premarket Clearances — Medtronic153 kỳ
- FDA Premarket Approvals (PMA & Supplements) — Medtronic153 kỳ
- FDA Medical Device Recall Events — Medtronic153 kỳ
- FDA MAUDE Adverse Event Reports — Medtronic Total153 kỳ
- ClinicalTrials.gov Newly Started Studies — Medtronic47 kỳ
- U.S. Federal Prime Contract Obligations — Medtronic Total ($M) ($M)117 kỳ
- U.S. PPI: Surgical & Medical Instrument Manufacturing (Index) (×)141 kỳ
Reportable Segments & Geographic Context (Database)
Consolidated Financial Statements Context (Database)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Medtronic
- Medtronic Form 10-Q — FY2027Q1 (filed 2026-09-03) ↗
- Medtronic SEC 8K_EARNINGS — FY2026Q4 (filed 2026-06-03) ↗
- Medtronic Form 10-K — FY2026 (filed 2026-06-18) ↗
- U.S. FDA openFDA Device Clearances, PMA, Recalls & MAUDE ↗
- Medtronic SEC 8K_EARNINGS — FY2027Q1 (filed 2026-09-01) ↗
- MiniMed Group Investor Presentation (September 2026) ↗
- Medtronic SEC 8K_EARNINGS — FY2023Q4 (filed 2023-05-25) ↗
- Medtronic FY2025 Irish Statutory Financial Statements ↗
- Medtronic Form DEF 14A Proxy — FY2026 (filed 2026-08-17) ↗
- NIH ClinicalTrials.gov Registry — Medtronic ↗
- USAspending.gov Federal Prime Contract Awards — Medtronic ↗
- Medtronic FY2026Q2 Earnings Presentation ↗
See a number that looks wrong?